Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates...

Prof Nicolas Girard - Institut Curie, Paris, France

Addition of relatlimab to nivolumab plus platinum-doublet chemo demonstrates improved clinical benefit in NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Trastuzumab deruxtecan effective against brain metastases in HER2-positive...

Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA

Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer ( Dr Nancy Lin - Dana-Farber Cancer Institute, Boston, USA )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival...

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach...

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Bladder cancer updates from the first half of 2024

Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo

Bladder cancer updates from the first half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo )

Trifluridine/tipiracil followed by regorafenib can be an effective treatment...

Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France

Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC ( Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Updates from ASCO 2024 in gastrointestinal tumours

Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center...

Updates from ASCO 2024 in gastrointestinal tumours ( Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, USA )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

More from ecancer